RT Journal Article
T1 Effectiveness of monopolar dielectric transmission of pulsed electromagnetic for multiple sclerosis-related pain: A pilot study
A1 Hochsprung, A.
A1 Escudero-Uribe, S.
A1 Ibanez-Vera, A. J.
A1 Izquierdo-Ayuso, G.
K1 Multiple sclerosis
K1 Pain
K1 Electrotherapy
K1 Radiofrequency
K1 Neuropathic pain
K1 Trigeminal neuralgia
K1 Electrical nerve-stimulation
K1 Quality-of-life
K1 Low-back-pain
K1 Biological tissues
K1 Spanish version
K1 Efficacy
K1 Management
K1 Mechanisms
K1 Frequency
K1 Fatigue
AB Introduction: Pain is highly prevalent in patients with multiple sclerosis (MS); it is chronic in 50% of cases and is classified as nociceptive, neuropathic, or mixed-type. Pain affects quality of life, sleep, and the activities of daily living. Electrotherapy is an interesting alternative or complementary treatment in the management of pain in MS, with new innovations constantly appearing.Material and methods: This study evaluates the effectiveness of treatment with monopolar dielectric transmission of pulsed electromagnetic fields (PEMF) for pain associated with MS. We performed a randomised, placebo-controlled clinical trial including 24 patients, who were assessed with the Brief Pain Inventory, the Multiple Sclerosis International Quality of Life questionnaire, the Beck Depression Inventory, and the Modified Fatigue Impact Scale.Results: Statistically significant improvements were observed in maximum and mean pain scores, as well as in the impact of pain on work, personal relationships, and sleep and rest. Not significant differences were found between the treatment and placebo groups.Conclusions: Treatment with PEMF may be effective in reducing pain in patients with MS, although further research is necessary to confirm its effectiveness over placebo and to differentiate which type of pain may be more susceptible to this treatment. (C) 2018 Sociedad Espanola de Neurologia. Published by Elsevier Espana, S.L.U.
PB Elsevier espana slu
SN 0213-4853
YR 2021
FD 2021-06-28
LK http://hdl.handle.net/10668/14599
UL http://hdl.handle.net/10668/14599
LA es
DS RISalud
RD Apr 8, 2025